Do GLP-1 drugs extend life? What the evidence shows
The difference between fewer events, an observed mortality signal and proven lifespan extension matters.
Search explainers, questions, and medicine profiles.
Every published article, newest first. Reporting, explainers, and practical guides on weight and metabolic health.
The difference between fewer events, an observed mortality signal and proven lifespan extension matters.
The randomized trial separates scale weight, lean soft tissue and strength—and leaves questions about everyday delivery.
The new class-wide action rests on rare trial events and real-world comparisons that need careful interpretation.
The scan findings offer a mechanism clue, but the analysis excludes people who stopped treatment or lacked paired scans.
The 68-week trial found about a two-point additional pain reduction versus placebo; percentage headlines and tolerability need separate scrutiny.
New sponsor-reported data add routine-care observations, with limits on drug comparisons and claims about liver scarring.
An exploratory GIPR finding raises a question about individual response, with no tested cutoff for choosing treatment.
Daily tracking in a mostly type 2 diabetes cohort shows why weight changes cannot stand in for mood assessment.
New research discussion puts shared meals and social connection in focus. Original qualitative studies show experiences, not a proven loneliness effect.